Triptoquinone A may be a useful candidate for the development of a drug as a potent inhibitor of iNOS gene over-expression. Triptoquinone A has anti-inflammatory activity, it prevents ndotoxin-or interleukin-1 beta-promoted induction of nitric oxide synthase in vascular smooth muscle, thus inhibiting development of L-arginine-induced vasorelaxation.